An independent reading room for the Epithalon and Epitalon literature

What Reviews Epitalon Is

Reviews Epitalon is an independent editorial project that publishes summaries of the peer-reviewed research literature on Epithalon and Epitalon — the synthetic tetrapeptide Ala-Glu-Asp-Gly studied primarily as a telomerase activator and pineal gland bioregulator.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'reviews' in our name is editorial framing: this is a site that reads and reviews the research record — the literature on Epithalon — with the care and critical attention a naturalist would bring to a field specimen. It is not a product review site, not an aggregate of customer testimonials, and not a vendor directory. The modifier does not imply that we are licensed medical reviewers or that we evaluate clinical outcomes in patients.

History of Epitalon Research: Khavinson and the St. Petersburg Institute

The Epithalon research record is rooted in one institution: the St. Petersburg Institute of Bioregulation and Gerontology, where Vladimir Khavinson and colleagues began studying Epithalamin (bovine pineal extract) in the 1970s. The synthetic tetrapeptide Epithalon — the four-amino-acid active fraction — was developed and characterized over the subsequent decades, with the telomerase-activation mechanism first formally described in 2003 ^[1].

Vladimir Nikolaevich Anisimov joined the longevity research strand in the early 2000s, contributing the rodent lifespan studies that remain the most-cited longevity data in the literature ^[3][4][14]. The melatonin normalization studies — in rhesus macaques and elderly human subjects — were conducted by Oleg Korkushko, Khavinson, and colleagues across 2001–2007 ^[5][6][7].

The most significant recent development is the 2025 study by Al-dulaimi, Thomas, Matta, and Roberts at Brunel University London, which independently confirmed dose-dependent telomere elongation in four human cell lines and identified divergent mechanisms by cell type ^[2]. This represents the first major external-institution replication of the central telomere claim — twenty-two years after the original Khavinson 2003 finding ^[1]. It is also the first confirmation published in a Western peer-reviewed journal by researchers with no institutional connection to the St. Petersburg group.

The single-group provenance limitation is acknowledged throughout this site. It is the most important caveat in the Epitalon literature, and a responsible reading of the record requires stating it plainly.

Editorial Standards

Every quantitative claim on this site traces to a numbered citation in the references list. We cite the specific publication, not secondary summaries. We do not extrapolate from animal data to human outcomes without explicitly marking the extrapolation.

Where the evidence is strong, we say so: the cell-line telomere elongation finding is reproduced and independently confirmed. Where the evidence is limited, we say that too: human lifespan data does not exist, and the rodent longevity data originates primarily from one laboratory.

We do not prescribe. We do not recommend doses. We do not evaluate products. We describe what was administered to which species at which dose by which route in which study — the language of a careful naturalist's field record, not a clinical leaflet.

This site does not have a commercial relationship with any Epithalon or Epitalon supplier. It does not contain affiliate links. It does not earn revenue from the purchase of any compound.